Gut and Intratumoral microbiota: Key to lung Cancer development and immunotherapy

IF 4.7 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2025-04-24 DOI:10.1016/j.intimp.2025.114677

Junlan Cai , Weiguang Zhang , Shujing Zhu , Tianxin Lin , Renyan Mao , Ningzi Wu , Peipei Zhang , Mingqiang Kang

{"title":"Gut and Intratumoral microbiota: Key to lung Cancer development and immunotherapy","authors":"Junlan Cai , Weiguang Zhang , Shujing Zhu , Tianxin Lin , Renyan Mao , Ningzi Wu , Peipei Zhang , Mingqiang Kang","doi":"10.1016/j.intimp.2025.114677","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer is a common malignant tumor worldwide with high incidence and mortality rates. Previous studies have claimed that the microbial community plays an integral role in the development and progression of lung cancer. Emerging evidence reveals that gut flora plays a key role in cancer formation and evolution by participating in mechanisms such as metabolism, regulation of inflammation and immune response. Not only the gut flora, but also the presence of intratumoral microbiota may influence lung cancer progression through multiple mechanisms. These research advances suggest that intestinal flora and intratumoral microbiota may not only serve as potential biomarkers for lung cancer, but may also be targets for therapy. However, current studies on both in lung cancer are still limited. Given this, this study aimed to systematically review the latest findings on the major bacterial species of the intestinal flora and their possible protective or harmful roles in the formation, progression, and metastasis of lung cancer. In addition, we analyzed the potential mechanisms by which the intratumoral microbiota affected lung cancer and elaborated on the potential roles of the gut flora and its metabolites, as well as the intratumoral microbiota, in modulating the efficacy of immunotherapy in lung cancer.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"156 ","pages":"Article 114677"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925006678","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is a common malignant tumor worldwide with high incidence and mortality rates. Previous studies have claimed that the microbial community plays an integral role in the development and progression of lung cancer. Emerging evidence reveals that gut flora plays a key role in cancer formation and evolution by participating in mechanisms such as metabolism, regulation of inflammation and immune response. Not only the gut flora, but also the presence of intratumoral microbiota may influence lung cancer progression through multiple mechanisms. These research advances suggest that intestinal flora and intratumoral microbiota may not only serve as potential biomarkers for lung cancer, but may also be targets for therapy. However, current studies on both in lung cancer are still limited. Given this, this study aimed to systematically review the latest findings on the major bacterial species of the intestinal flora and their possible protective or harmful roles in the formation, progression, and metastasis of lung cancer. In addition, we analyzed the potential mechanisms by which the intratumoral microbiota affected lung cancer and elaborated on the potential roles of the gut flora and its metabolites, as well as the intratumoral microbiota, in modulating the efficacy of immunotherapy in lung cancer.

查看原文本刊更多论文

肠道和肿瘤内微生物群：肺癌发展和免疫治疗的关键

肺癌是世界范围内常见的恶性肿瘤，发病率高，死亡率高。先前的研究表明，微生物群落在肺癌的发生和发展中起着不可或缺的作用。越来越多的证据表明，肠道菌群通过参与代谢、炎症调节和免疫反应等机制，在癌症的形成和进化中起着关键作用。不仅肠道菌群，肿瘤内微生物群的存在也可能通过多种机制影响肺癌的进展。这些研究进展表明，肠道菌群和肿瘤内微生物群不仅可以作为肺癌的潜在生物标志物，而且可能是治疗的靶点。然而，目前对两者在肺癌中的研究仍然有限。鉴于此，本研究旨在系统综述肠道菌群中主要细菌种类及其在肺癌形成、进展和转移中可能起到的保护或有害作用的最新发现。此外，我们分析了肿瘤内微生物群影响肺癌的潜在机制，并阐述了肠道菌群及其代谢物以及肿瘤内微生物群在调节肺癌免疫治疗疗效中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.